Want to see AIM full AI Analyst Report?
Top Page
AIM ImmunoTech
(NYSE MKT:AIM)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.29
▼(-76.48% Downside)
Action:Reiterated
Date:06/15/26
The score is weighed down primarily by weak financial performance (minimal revenue, large ongoing losses, and persistent cash burn) and a weak technical trend (trading below major moving averages). Corporate events provide some offset via improved listing compliance and fresh capital, but valuation remains constrained by negative earnings and no stated dividend yield.
Positive Factors
Improved capital and listing compliance
Restoring NYSE compliance via sizable financings materially reduces near-term delisting risk and provides durable runway to advance clinical programs. Stronger equity supports manufacturing, trial enrollment and regulatory filings, improving the company’s ability to execute multi-month development milestones.
Negative Factors
High, persistent cash burn
Sustained negative operating and free cash flow with negligible revenue indicates the company is not self-financing R&D. Over the next several months this structural cash burn necessitates external funding to complete trials, increasing execution risk and dependency on capital markets irrespective of clinical progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved capital and listing compliance
Restoring NYSE compliance via sizable financings materially reduces near-term delisting risk and provides durable runway to advance clinical programs. Stronger equity supports manufacturing, trial enrollment and regulatory filings, improving the company’s ability to execute multi-month development milestones.
Read all positive factors
AIM ImmunoTech (AIM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.04M
Dividend YieldN/A
Average Volume (3M)39.67M
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue Growth-35.62%
EPS Growth70.55%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.82
Shares Outstanding27,724,245
10 Day Avg. Volume1,293,487
30 Day Avg. Volume39,669,069
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap0.01
Enterprise Value/Revenue1.27
Enterprise Value/Gross Profit-0.96
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.25Price Target Upside320.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$100.00K
AIM ImmunoTech Business Overview & Revenue Model
Company Description
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug...
How the Company Makes Money
null...
AIM ImmunoTech Earnings Call Summary
Earnings Call Date:Mar 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant clinical and strategic advancements, including new studies, leadership expansion, and cost reductions. However, financial challenges were noted, with low cash reserves and a risk of delisting from the stock exchange, which the company is actively working to address.Positive Updates
New Clinical Study with AstraZeneca
AIM ImmunoTech announced plans to conduct a new clinical study evaluating Ampligen in combination with AstraZeneca's intranasal influenza vaccine, FluMist, for influenza, including avian flu.
Negative Updates
Low Cash Reserves
As of December 31, 2024, AIM ImmunoTech had approximately $4 million in cash, cash equivalents, and marketable securities, highlighting potential financial constraints.
Read all updates
Q4-2024 Updates
Positive
Negative
New Clinical Study with AstraZeneca
AIM ImmunoTech announced plans to conduct a new clinical study evaluating Ampligen in combination with AstraZeneca's intranasal influenza vaccine, FluMist, for influenza, including avian flu.
Read all positive updates
Company Guidance
During the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call, CEO Thomas Equels provided extensive guidance on the company's progress and future plans. Key clinical updates included the continuation into Phase 2 of the DURIPANC trial evaluating Ampligen with AstraZeneca's Imfinzi for metastatic pancreatic cancer, and the completion of the AMP-518 study on post-COVID conditions. Financial metrics revealed that research and development expenses decreased to $6.2 million from $10.9 million the previous year, while general and administrative expenses fell to $13.7 million from $21.1 million. The company held approximately $4 million in cash and equivalents as of December 31, 2024. Strategic initiatives to maintain NYSE American listing, including a potential reverse stock split, were also discussed. The call concluded with a commitment to advancing Ampligen's potential across several high-need medical areas.AIM ImmunoTech Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 88.00K | 170.00K | 202.00K | 141.00K | 135.00K |
| Gross Profit | -250.00K | 139.00K | 160.00K | 141.00K | -715.00K |
| EBITDA | -12.94M | -16.49M | -28.72M | -19.19M | -18.29M |
| Net Income | -13.96M | -17.32M | -28.96M | -19.45M | -19.13M |
Balance Sheet | |||||
| Total Assets | 5.78M | 8.61M | 19.38M | 40.49M | 57.70M |
| Cash, Cash Equivalents and Short-Term Investments | 993.00K | 3.98M | 13.07M | 34.19M | 48.27M |
| Total Debt | 4.90M | 2.94M | 718.00K | 837.00K | 149.00K |
| Total Liabilities | 15.56M | 9.93M | 9.15M | 2.02M | 820.00K |
| Stockholders Equity | -9.78M | -1.32M | 10.23M | 38.47M | 56.88M |
Cash Flow | |||||
| Free Cash Flow | -11.34M | -14.91M | -21.85M | -16.38M | -14.60M |
| Operating Cash Flow | -10.96M | -14.89M | -21.27M | -16.11M | -13.96M |
| Investing Cash Flow | 1.85M | 4.71M | -832.00K | 10.99M | -631.00K |
| Financing Cash Flow | 10.39M | 6.44M | 485.00K | 80.00K | 8.19M |
AIM ImmunoTech Technical Analysis
Negative
1.25
Price Trends
0.41
Negative
0.58
Negative
1.15
Negative
Market Momentum
-0.05
Positive
40.41
Neutral
30.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIM, the sentiment is Negative. The current price of 1.25 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.41, and above the 200-day MA of 1.15, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 40.41 is Neutral, neither overbought nor oversold. The STOCH value of 30.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIM.
AIM ImmunoTech Risk Analysis
AIM ImmunoTech disclosed 42 risk factors in its most recent earnings report. AIM ImmunoTech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AIM ImmunoTech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $41.97M | -0.72 | 288.40% | ― | ― | 86.10% | |
47 Neutral | $20.73M | -0.07 | -356.99% | ― | ― | -152.00% | |
43 Neutral | $8.04M | -0.16 | 261.84% | ― | -35.62% | 70.55% | |
42 Neutral | $5.23M | -0.18 | -281.30% | ― | ― | 86.07% |
* Healthcare Sector Average
AIM
AIM ImmunoTech
0.29
-9.06
-96.91%
GTBP
GT Biopharma
0.45
-1.84
-80.48%
PMCB
PharmaCyte Biotech
0.70
-0.40
-36.13%
PCSA
Processa Pharmaceuticals
1.97
-3.78
-65.74%
APLM
Apollomics
18.80
13.10
229.82%
AIM ImmunoTech Corporate Events
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
AIM ImmunoTech Regains NYSE American Listing Compliance
Positive
Jun 15, 2026
On June 12, 2026, AIM ImmunoTech regained compliance with NYSE American’s continued listing standards related to stockholders’ equity, as confirmed by NYSE Regulation and disclosed on June 15. The move removes the “.BC” bel...
Business Operations and StrategyPrivate Placements and Financing
AIM ImmunoTech Raises Capital via Registered Direct Offering
Positive
Jun 11, 2026
On June 9, 2026, AIM ImmunoTech Inc. entered into definitive agreements with institutional investors for a registered direct offering and concurrent private placement of common stock and warrants, priced at-the-market under NYSE American rules. Th...
Business Operations and StrategyRegulatory Filings and Compliance
AIM ImmunoTech Updates Bylaws on Shareholder Voting Standards
Neutral
Jun 10, 2026
On June 9, 2026, AIM ImmunoTech Inc.’s Board of Directors approved an amendment to its Amended and Restated Bylaws to revise the voting standard for stockholder proposals other than the election of directors. Under the new standard, such pro...
Business Operations and StrategyProduct-Related Announcements
AIM ImmunoTech Highlights Ampligen’s Emerging Ebola Treatment Potential
Positive
Jun 4, 2026
On June 4, 2026, AIM ImmunoTech released a Virtual Investor “What This Means” video segment and an updated Ebola-focused corporate presentation discussing preclinical findings on Ampligen’s potential as a prophylactic or early-on...
Business Operations and StrategyPrivate Placements and Financing
AIM ImmunoTech Announces Equity Offering to Bolster Capital
Positive
May 21, 2026
On May 20, 2026, AIM ImmunoTech Inc. entered into a securities purchase agreement with institutional investors for a registered direct offering of 7,519,351 shares of common stock at $0.325 per share, alongside a concurrent private placement of wa...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
AIM ImmunoTech Strengthens Equity Position and Financial Flexibility
Positive
May 19, 2026
On May 19, 2026, AIM ImmunoTech reported that stockholder equity rose to approximately $2.1 million as of March 31, 2026, a swing of about $11.9 million from a stockholder deficit of roughly $9.8 million at December 31, 2025, aided by additional e...
Business Operations and StrategyProduct-Related Announcements
AIM ImmunoTech Highlights Ampligen Progress in Pancreatic Cancer
Positive
May 14, 2026
On May 14, 2026, AIM ImmunoTech highlighted progress for its lead drug Ampligen in a Virtual Investor Key Opinion Leader segment featuring Erasmus Medical Center surgeon and consultant Prof. Casper H.J. van Eijck and CEO Thomas K. Equels. The disc...
Private Placements and FinancingRegulatory Filings and Compliance
AIM ImmunoTech Raises Capital Through Warrant Exercise Inducement
Neutral
May 12, 2026
On May 8, 2026, AIM ImmunoTech closed a warrant exercise inducement transaction in which existing warrant holders agreed to exercise warrants for 7,451,920 shares of common stock at a reduced exercise price of $0.48 per share, providing the compan...
Business Operations and StrategyPrivate Placements and Financing
AIM ImmunoTech Induces Warrant Exercises to Raise Capital
Positive
May 8, 2026
On May 7, 2026, AIM ImmunoTech entered into a warrant exercise inducement agreement with existing warrant holders covering several prior warrant series, cutting the exercise price on those securities to $0.48 per share and prompting immediate cash...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
AIM ImmunoTech Expands At-The-Market Equity Offering Capacity
Neutral
Apr 10, 2026
On April 10, 2026, AIM ImmunoTech Inc. amended its existing Equity Distribution Agreement with Maxim Group LLC, which had previously capped at-the-market sales of its common stock at $3 million. The amendment removes that cap, allowing the company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.